Bitcoin Rally At Risk: This Critical Resistance Could End BTC’s Bullish Run
Bitcoin's rally is at risk as it faces crucial resistance at $82,500.
NewsBTC1 min read
OpenAI's New AI Model Rosalind Could Shave Years Off Drug Discovery. You Probably Can't Use It
TL;DR
OpenAI has introduced GPT-Rosalind, an AI model aimed at speeding up drug discovery processes. However, access to the model is limited due to biosecurity concerns.
Key points
- OpenAI unveiled GPT-Rosalind for drug discovery workflows
- Model shows strong benchmark gains
- Real-world impact remains limited
- Access is restricted due to biosecurity concerns
- First in OpenAI's Life Sciences model series
Mentioned in this story
Rosalind FranklinOpenAI
In brief
- OpenAI unveiled GPT-Rosalind to accelerate drug discovery workflows.
- Benchmarks show strong gains, but real-world impact remains constrained .
- Access is tightly restricted amid rising biosecurity concerns.
OpenAI just named its first domain-specific AI model after Rosalind Franklin—the British chemist whose X-ray crystallography work helped reveal DNA's double helix, and who was famously denied credit for it during her lifetime.
GPT-Rosalind, unveiled Thursday, is a purpose-built reasoning model for biology, drug discovery, and translational medicine. It's the first in what OpenAI is calling a Life Sciences model series—a direct play for a market where many specialized labs from universities to Google DeepMind are all jostling for position.
Getting a drug from target discovery to regulatory approval in the U.S. takes 10 to 15 years on average according to experts.. Most of that time disappears not in eureka moments, but in the grind: parsing thousands of papers, querying databases, designing reagents, and interpreting ambiguous results. This is what GPT-Rosaling is trying to tackle.
OpenAI argues the model can compress that early-stage work. As the company put it, GPT-Rosalind is designed to help scientists "explore more possibilities, surface connections that might otherwise be missed, and arrive at better hypotheses sooner."
The benchmarks back up at least some of that ambition. On BixBench—a benchmark built around real-world bioinformatics tasks—GPT-Rosalind logged a 0.751 pass rate, the top score among models with published results. On LABBench2, it outperformed its predecessor GPT-5.4 on six out of eleven tasks.
GPT-Rosalind Beats GPT 5.4 in every single case involving life science, but it’s a highly specific model that will underperform in anything other than that.
OpenAI also announced Dyno Therapeutics will help test and evaluate its model based on unpublished RNA sequences to rule out memorization. GPT-Rosalind's best-of-ten submissions ranked above the 95th percentile of human experts on sequence prediction tasks, and around the 84th percentile on generation.
Q&A
What is GPT-Rosalind and how does it relate to drug discovery?
GPT-Rosalind is OpenAI's new AI model designed to enhance drug discovery workflows by providing advanced reasoning capabilities in biology and translational medicine.
Why is access to GPT-Rosalind restricted?
Access to GPT-Rosalind is tightly restricted due to rising biosecurity concerns related to its application in drug discovery.
How long does drug discovery typically take in the U.S.?
On average, drug discovery in the U.S. takes about 10 to 15 years from target discovery to regulatory approval.
Who was Rosalind Franklin and why is the model named after her?
Rosalind Franklin was a British chemist whose work on X-ray crystallography was crucial in revealing the structure of DNA, and she was historically overlooked for her contributions.
